IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

Adriana Olar; Khalida M. Wani; Kristin D. Alfaro-Munoz; Lindsey E. Heathcock; Hinke F. van Thuijl; Mark R. Gilbert; Terri S. Armstrong; Erik P. Sulman; Daniel P. Cahill; Elizabeth Vera-Bolanos; Ying Yuan; Jaap C. Reijneveld; Bauke Ylstra; Pieter Wesseling; Kenneth D. Aldape

doi:10.1007/s00401-015-1398-z

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

Adriana Olar^*, Khalida M. Wani, Kristin D. Alfaro-Munoz, Lindsey E. Heathcock, Hinke F. van Thuijl, Mark R. Gilbert, Terri S. Armstrong, Erik P. Sulman, Daniel P. Cahill, Elizabeth Vera-Bolanos, Ying Yuan, Jaap C. Reijneveld, Bauke Ylstra, Pieter Wesseling, Kenneth D. Aldape

^*Corresponding author for this work

Department of Pathology

Research output: Contribution to journal › Article › Academic › peer-review

30 Citations (Scopus)

Abstract

Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and mitotic index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II–III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and IDH-wild type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95 % confidence interval (CI) = 0.91–1.61] compared to IDH-wild type tumors (HR = 1.74, 95 % CI = 0.95–3.16). Using a dichotomized mitotic index cut-off of 4/1000 tumor cells, we found that while mitotic index was significantly associated with outcome in IDH-wild type tumors (log-rank p

Original language	English
Pages (from-to)	585-596
Number of pages	12
Journal	Acta Neuropathologica
Volume	129
Issue number	4
DOIs	https://doi.org/10.1007/s00401-015-1398-z
Publication status	Published - 1 Apr 2015

Keywords

1p/19q
Diffuse glioma
IDH
Outcome
pHH3
WHO grade

Access to Document

10.1007/s00401-015-1398-z

Cite this

Olar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., Yuan, Y., Reijneveld, J. C., Ylstra, B., Wesseling, P., & Aldape, K. D. (2015). IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathologica, 129(4), 585-596. https://doi.org/10.1007/s00401-015-1398-z

@article{ed9f3add279d49d397c4fe5477355bd9,

title = "IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas",

abstract = "Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and mitotic index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II–III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and IDH-wild type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95 % confidence interval (CI) = 0.91–1.61] compared to IDH-wild type tumors (HR = 1.74, 95 % CI = 0.95–3.16). Using a dichotomized mitotic index cut-off of 4/1000 tumor cells, we found that while mitotic index was significantly associated with outcome in IDH-wild type tumors (log-rank p ",

keywords = "1p/19q, Diffuse glioma, IDH, Outcome, pHH3, WHO grade",

author = "Adriana Olar and Wani, {Khalida M.} and Alfaro-Munoz, {Kristin D.} and Heathcock, {Lindsey E.} and {van Thuijl}, {Hinke F.} and Gilbert, {Mark R.} and Armstrong, {Terri S.} and Sulman, {Erik P.} and Cahill, {Daniel P.} and Elizabeth Vera-Bolanos and Ying Yuan and Reijneveld, {Jaap C.} and Bauke Ylstra and Pieter Wesseling and Aldape, {Kenneth D.}",

year = "2015",

month = apr,

day = "1",

doi = "10.1007/s00401-015-1398-z",

language = "English",

volume = "129",

pages = "585--596",

journal = "Acta Neuropathologica",

issn = "0001-6322",

publisher = "Springer",

number = "4",

}

Olar, A, Wani, KM, Alfaro-Munoz, KD, Heathcock, LE, van Thuijl, HF, Gilbert, MR, Armstrong, TS, Sulman, EP, Cahill, DP, Vera-Bolanos, E, Yuan, Y, Reijneveld, JC, Ylstra, B, Wesseling, P & Aldape, KD 2015, 'IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas', Acta Neuropathologica, vol. 129, no. 4, pp. 585-596. https://doi.org/10.1007/s00401-015-1398-z

TY - JOUR

T1 - IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

AU - Olar, Adriana

AU - Wani, Khalida M.

AU - Alfaro-Munoz, Kristin D.

AU - Heathcock, Lindsey E.

AU - van Thuijl, Hinke F.

AU - Gilbert, Mark R.

AU - Armstrong, Terri S.

AU - Sulman, Erik P.

AU - Cahill, Daniel P.

AU - Vera-Bolanos, Elizabeth

AU - Yuan, Ying

AU - Reijneveld, Jaap C.

AU - Ylstra, Bauke

AU - Wesseling, Pieter

AU - Aldape, Kenneth D.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and mitotic index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II–III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and IDH-wild type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95 % confidence interval (CI) = 0.91–1.61] compared to IDH-wild type tumors (HR = 1.74, 95 % CI = 0.95–3.16). Using a dichotomized mitotic index cut-off of 4/1000 tumor cells, we found that while mitotic index was significantly associated with outcome in IDH-wild type tumors (log-rank p

AB - Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of tumors. The role of tumor grade and mitotic index in patient outcome has not been evaluated following stratification by IDH mutation status. To address this, we interrogated 558 WHO grade II–III diffuse gliomas for IDH1/2 mutations and investigated the prognostic impact of WHO grade within IDH-mutant and IDH-wild type tumor subsets independently. The prognostic impact of grade was modest in IDH-mutant [hazard ratio (HR) = 1.21, 95 % confidence interval (CI) = 0.91–1.61] compared to IDH-wild type tumors (HR = 1.74, 95 % CI = 0.95–3.16). Using a dichotomized mitotic index cut-off of 4/1000 tumor cells, we found that while mitotic index was significantly associated with outcome in IDH-wild type tumors (log-rank p

KW - 1p/19q

KW - Diffuse glioma

KW - IDH

KW - Outcome

KW - pHH3

KW - WHO grade

UR - http://www.scopus.com/inward/record.url?scp=84939979467&partnerID=8YFLogxK

U2 - 10.1007/s00401-015-1398-z

DO - 10.1007/s00401-015-1398-z

M3 - Article

C2 - 25701198

AN - SCOPUS:84939979467

SN - 0001-6322

VL - 129

SP - 585

EP - 596

JO - Acta Neuropathologica

JF - Acta Neuropathologica

IS - 4

ER -

IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this